Hepatocellular Carcinoma : Updates to Screening and Diagnosis
Copyright © 2018 by the National Comprehensive Cancer Network..
In what is considered to be "a global problem," liver cancer has tripled in incidence in the United States over the past 20 to 30 years, and is now present in 7 per 100,000 Americans. Thus, screening for disease should be at the forefront to effectively treat high-risk populations. At the 2018 NCCN 23rd Annual Conference, Dr. Anne M. Covey discussed the updated NCCN Guidelines for the screening and diagnosis of hepatocellular carcinoma, which place ultrasound as the most cost-effective and least toxic primary screening option, with a screening interval of approximately 6 months for individuals considered to be at high risk.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 16(2018), 5S vom: 22. Mai, Seite 663-665 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Covey, Anne M [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 21.10.2019 Date Revised 31.03.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.6004/jnccn.2018.0052 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM284308153 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM284308153 | ||
003 | DE-627 | ||
005 | 20231225042920.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.6004/jnccn.2018.0052 |2 doi | |
028 | 5 | 2 | |a pubmed24n0947.xml |
035 | |a (DE-627)NLM284308153 | ||
035 | |a (NLM)29784751 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Covey, Anne M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hepatocellular Carcinoma |b Updates to Screening and Diagnosis |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.10.2019 | ||
500 | |a Date Revised 31.03.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2018 by the National Comprehensive Cancer Network. | ||
520 | |a In what is considered to be "a global problem," liver cancer has tripled in incidence in the United States over the past 20 to 30 years, and is now present in 7 per 100,000 Americans. Thus, screening for disease should be at the forefront to effectively treat high-risk populations. At the 2018 NCCN 23rd Annual Conference, Dr. Anne M. Covey discussed the updated NCCN Guidelines for the screening and diagnosis of hepatocellular carcinoma, which place ultrasound as the most cost-effective and least toxic primary screening option, with a screening interval of approximately 6 months for individuals considered to be at high risk | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a alpha-Fetoproteins |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 16(2018), 5S vom: 22. Mai, Seite 663-665 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2018 |g number:5S |g day:22 |g month:05 |g pages:663-665 |
856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2018.0052 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2018 |e 5S |b 22 |c 05 |h 663-665 |